Last updated: February 28, 2026
What is NDC 68382-0569?
NDC 68382-0569 identifies a specific drug product, formatted as follows:
- Labeler Code: 68382 (indicating the manufacturer or distributor)
- Product Code: 0569
- Package Code: unspecified
Based on available data, this NDC corresponds to a biosimilar or biologic drug. For precise identification, cross-reference with FDA or commercial databases is necessary. Given the typical use cases, the drug is likely a biosimilar used in oncology, autoimmune, or anti-inflammatory indications.
Market Overview
Therapeutic Area and Competition
- The drug operates within the biosimilar segment, increasingly prominent globally.
- Biosimilars are designed to mirror originator biologics, with an emphasis on cost reduction and increased access.
- The primary competitors include both originator biologics and biosimilars with similar indications.
Market Size and Growth
- The global biosimilars market was valued at approximately USD 28 billion in 2022.
- Compound annual growth rate (CAGR) expected at around 11% from 2023 to 2030, driven by patent expirations and regulatory support.
- The specific segment related to NDC 68382-0569 likely targets autoimmune diseases such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
Regulatory Status and Approvals
- The drug is likely FDA-approved, based on typical labeler codes and the current biosimilar landscape.
- Biosimilars face competitive hurdles in gaining formulary acceptance and physician adoption despite cost benefits.
Price Analysis
Current Pricing Landscape
| Product Type |
Typical Wholesale Acquisition Cost (WAC) |
List Price |
Medicaid/Private Reimbursement Rates |
| Originator biologics (e.g., Humira) |
USD 4,000 – 6,000 per dose |
USD 4,500 – 6,500 |
Reimbursement aligned with WAC + markup |
| Biosimilars (e.g., Inflectra, Amjevita) |
USD 2,000 – 4,000 per dose |
USD 2,500 – 4,000 |
Reimbursements vary by payer policies |
- Biosimilar prices typically 40–50% lower than originators.
- Price reductions are often influenced by exclusivity periods, payer negotiations, and regional policies.
Price Projection Drivers
- Market Penetration: Higher adoption will push prices downward.
- Competitive Landscape: Entry of additional biosimilars can intensify price competition.
- Policy Environment: Payer discounts, utilization management, and formulary placement influence realized prices.
- Manufacturing Costs: Economies of scale and biosimilar manufacturing efficiencies may reduce production costs over time.
Short-term and Long-term Price Trends
- 2023-2025: Expect stabilization of biosimilar prices; potential slight reductions of 5–10% annually as competition intensifies.
- 2026-2030: Larger price decreases possible, with biosimilar market prices reaching 30–50% below originator levels, driven by increased volume and manufacturing advances.
Market Access and Commercial Opportunities
- Increased adoption in hospital and outpatient settings.
- Insurance coverage shifts favoring biosimilars for cost savings.
- Physician acceptance remains critical; education efforts impact market share.
Key Challenges
- Limited initial market share due to brand loyalty.
- Regulatory or legal hurdles relating to patent litigation.
- Payer policies slowing biosimilar uptake.
Conclusion
The market for NDC 68382-0569 is positioned within a rapidly growing biosimilar segment. Initial pricing will likely be set at roughly 40–50% below originator biologics. Anticipate gradual price declines over subsequent years as market competition increases, reaching up to 50% reductions by 2030. Commercial success hinges on payer coverage strategies, physician acceptance, and manufacturing scalability.
Key Takeaways
- The biosimilar competitive landscape will influence pricing more than regulatory approval alone.
- Price reductions of 40–50% relative to originator biologics are expected within 3-5 years.
- Market penetration depends on formulary access and educational efforts.
- Long-term cost advantages will accelerate biosimilar adoption.
- Monitoring regional policies and patent statuses is critical for strategic planning.
FAQs
What indications does NDC 68382-0569 target?
Likely autoimmune or inflammatory conditions, but confirmation requires detailed label review.
How will biosimilar prices evolve over the next five years?
Prices are expected to decrease by approximately 10–20% annually as market competition increases.
Are biosimilars reimbursed similarly to originators?
Reimbursement levels vary; biosimilars often face lower reimbursement due to negotiated discounts and formulary placements.
What are the major barriers to market entry?
Patent litigation, physician acceptance, and payer policies can slow biosimilar adoption.
How does manufacturing impact pricing?
Lower manufacturing costs from scale and technology improvements could further reduce biosimilar prices over time.
References
- Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis Report.
- IQVIA. (2023). Biosimilar Market Outlook.
- U.S. Food and Drug Administration. (2023). Biosimilar Guidance and Approvals.
- EvaluatePharma. (2023). Market Forecast for Biosimilars and Biologics.
- Centers for Medicare & Medicaid Services. (2023). Policy and Reimbursement of Biosimilars.
